The Spot sign and Tranexamic acid On Preventing ICH growth - AUStralasia Trial (STOP-AUST): Protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial
Atte Meretoja, Leonid Churilov, Bruce CV Campbell, Richard I Aviv, Nawaf Yassi, Christen Barras, Peter Mitchell, Bernard Yan, Harshal Nandurkar, Christopher Bladin, Tissa Wijeratne, Neil J Spratt, Jim Jannes, Jonathan Sturm, Jayantha Rupasinghe, Jorge Zavala, Andrew Lee, Timothy Kleinig, Romesh Markus, Candice Delcourt Show all
International Journal of Stroke | SAGE PUBLICATIONS LTD | Published : 2014
Dr Meretoja has consulted for Boehringer Ingelheim. Dr Campbell has consulted for Lundbeck and received speaker's honoraria from Boehringer Ingelheim and Novartis. Dr Yan has received speaker's honoraria from Boehringer Ingelheim and educational grants from Bayer and CSL. Dr Nandurkar has consulted for Sanofi, Bayer, Pfizer, Alexion, GSK, and Hospira. Dr Sturm has received speaker's honoraria form Boehringer Ingelheim, Bayer, and Pfizer. Dr Markus has served on advisory board for Boehringer Ingelheim. Dr Levi served on advisory boards for Pfizer and Boehringer Ingelheim. Dr Donnan has consulted for Boehringer Ingelheim, Sanofi, Bayer, and Lundbeck. Dr Davis has served on advisory boards for Boehringer Ingelheim, Ever Pharma, and Sanofi-Aventis. He previously consulted for Novo Nordisk.